The ADPGK Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from HeLa cells with targeted disruption of the ADPGK gene. This product provides a heterogeneous loss-of-function model, avoiding clonal selection artifacts, suitable for metabolic research applications.
HeLa cells are an HPV18-immortalized human cervical adenocarcinoma epithelial line established in 1951, widely used in cancer biology for their rapid growth and well-characterized metabolic profile. As a cervical cancer model, HeLa cells exhibit high glycolytic activity and are commonly employed to study tumor metabolism and hypoxia responses, providing a relevant host for ADPGK knockout studies.
ADPGK encodes an ADP-dependent glucokinase that phosphorylates glucose to glucose-6-phosphate using ADP as a phosphate donor, enabling glycolysis under ATP-limited conditions. Its expression is induced by HIF-1?? and modulated by PI3K/AKT signaling and glucose deprivation. The enzyme requires magnesium cofactors and generates glucose-6-phosphate, which feeds glycolysis and the pentose phosphate pathway, producing lactate, NADPH, and ribose-5-phosphate. ADPGK interacts within a metabolic network including HK2, G6PD, PGD, TKT, PFKL, PKM2, LDHA, and MCT4. Knockout of ADPGK disrupts this alternative glycolytic route, reducing glycolytic flux and pentose phosphate pathway activity under metabolic stress.
In HeLa cells, ADPGK loss impairs metabolic adaptation during hypoxia and ATP depletion, as the alternative phosphorylation pathway is critical for maintaining energy and biosynthetic precursors. This sensitization highlights a metabolic vulnerability in cancer cells, making the knockout model valuable for probing hypoxia-induced metabolic reprogramming and identifying targets for anti-cancer therapies.
These polyclonal knockout cells are suited for cancer metabolism studies, hypoxia adaptation research, and metabolic drug target validation. Common assays include Western blotting, RT-qPCR, glucose uptake and lactate production measurements, Seahorse extracellular flux analysis, cell viability under hypoxia, metabolomic profiling, and RNA-seq. The mixed population format also supports high-throughput screening for metabolic modulators. For further technical details or experimental design support, please contact Ascent Research.
